Durbin
  • Managed Access Programs
  • Imports (Unlicensed Medicines)
  • International Sales
  • Clinical Trial Supply
  • Bespoke Specialist Distribution
  • Sales to NGOs & Charities
  • Sexual Health Supplies
  • Durbin USA
  • About Us
  • News
  • Contact Us
  • Join our Mailing List

    Privacy: Our mailing list will only be used to send you relevant Durbin updates and information. Please click here to see our full Privacy Policy.

    Full Name
    Company
    Email Address


    News

    Atlantic Pharmaceuticals appoints Durbin to operate its world-wide Named Patient Supply program

    23 July 2013

    Atlantic Pharmaceuticals Limited (Atlantic Pharmaceuticals), an international specialist-led healthcare company, based in Cambridge UK, announces that it has appointed Durbin PLC (Durbin) as its worldwide distributor for the Alicaforsen Named Patient Supply program (NPS).

    Durbin is a specialist pharmaceutical supplier distributing pharmaceuticals to 180 different countries with extensive experience in the distribution of unlicensed medications.

    Chief Executive Officer of Atlantic Pharmaceuticals - Toby Wilson Waterworth said: “Atlantic Pharmaceuticals has seen increased interest in Alicaforsen from the medical community. Internationally, physicians have been using the drug to treat unmet medical need. As a result of increasing requests Atlantic Pharmaceuticals needs an experienced partner with a track record, global reach, international regulatory expertise and an inclusive partnership approach. Durbin meets these criteria and we are pleased to be working with them.”

    CEO of Durbin – Leslie Morgan OBE said: “Atlantic Pharmaceuticals is a progressive company run by a very experienced leadership team and we are pleased to be working in partnership with them. In our 50 years of trading we have built up a high level of expertise running programs like this. These programs are about putting patients’ needs first. It is great to be working with Atlantic, who share our dedication to improving the patients’ lives.”

    Full details of the program can be obtained from Durbin.

    For further information, please contact:

    Robert Donnell, Head of Business Development, Durbin PLC on
    +44 (0)20 8869 6513 or email r.donnell@durbin.co.uk

    Toby Wilson Waterworth, CEO, Atlantic Pharmaceuticals on
    +44 (0)1799 513 391 or email info@atlantichc.com

    Press Releases